CARLSBAD, Calif., Oct. 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharmaceuticals' Third Quarter 2014 Financial Results and Highlights Conference Call
Friday, November 7 at 11:30 a.m. ET / 8:30 a.m. PT
Live on the Internet. Simply log onto our websi...
CARLSBAD, Calif., Oct. 30, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com. A replay will be available on the Isis website within 48 hours a...
Phase 3 ENDEAR study in infants with SMA enrolling; on track to initiate Phase 3 study in children with SMA later this year
Isis to host a webcast at 11:30 a.m. EDT on Friday, October 10
CARLSBAD, Calif., Oct. 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today provided an update on its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 19th International World Muscle Society (WMS) Congress in Ber...
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
"ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline. We have patients who have...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.